Lancet Rheumato: Study on the safety of hydroxychloroquine for the treatment of rheumatoid arthritis.

Hydroxychloroquine is a commonly used treatment for rheumatoid arthritis, but it is urgently authorized to treat Covid-19 pneumonia, resulting in many adverse events, so many rheumatoid arthritis patients question the safety of hydroxychloroquine.
recently assessed the risk of hydroxychloroquine alone and in combination with azithromycin in routine care for patients with rheumatoid arthritis.
This study is a multi-country retrospective study comparing adverse events caused by the first use of hydroxychloroquine or lysolone sulfonate in patients aged 18 years or older with rheumatoid arthritis, followed for more than 30 days, and examined 16 serious adverse events.
also compared the adverse event differences between hydroxychloroquine combined with azithromycin and hydroxychloroquine combined with amoxilin.
study included 956,374 patients with hydroxychloroquine, 310,350 users of lyuse sulfonate, 323,122 users of hydroxychloroquine combined with azithromycin, and 35,1956 patients with hydroxychloroquine combined with amoxycin.
the use of hydroxychloroquine did not increase the risk of adverse events in patients for 30 days compared to lysolone, but long-term use of hydroxychloroquine appeared to be associated with an increase in cardiovascular mortality (HR=1.65).
combination of hydroxychloroquine and azithromycin increased the risk of cardiovascular mortality (2.19), chest or angina (1.15) and heart failure (1.22) for 30 days.
study found that short-term use of hydroxychloroquine in patients with rheumatoid arthritis did not increase the risk of adverse events, but long-term use led to an increased risk of cardiovascular death, and even short-term combined use of hydroxychloroquine and azithromycin led to an increased risk of heart failure and cardiovascular death.
.